Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 11/20 | 0.90 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.90 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.90 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.67 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.67 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15254264 | 0.98 | LTA4H (0.87) | LTA4HPTGS2PTGS1PSMB1PSMB5 | |
| SCHEMBL23724061 | 0.98 | LTA4H (0.87) | LTA4HPTGS2PTGS1PSMB1PSMB5 | |
| SCHEMBL3937460 | 0.98 | LTA4H (0.87) | LTA4HPTGS2PTGS1PSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL3997911 | 0.96 | LTA4H (0.84) | LTA4HPTGS2PTGS1PSMB1PSMB5 | |
| SCHEMBL4457910 | 0.91 | LTA4H (0.76) | LTA4HPTGS2PTGS1HRH3KCNH2 | |
| SCHEMBL3398830 | 0.91 | LTA4H (0.75) | LTA4HPTGS2PTGS1PSMB1PSMB5 | |
| SCHEMBL2968936 | 0.89 | HRH3 (0.75) | LTA4HPTGS2PTGS1HRH3KCNH2 | |
| SCHEMBL16359559 | 0.89 | LTA4H (0.73) | LTA4HPTGS2PTGS1HRH3KCNH2 | |
| SCHEMBL4465869 | 0.89 | HRH3 (0.75) | LTA4HPTGS2PTGS1HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL736843 | 0.88 | HRH3 (0.73) | LTA4HPTGS2PTGS1HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | claimed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | claimed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | claimed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12391676-B2 | BRD4-JAK2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-120081789-A | Pyrazole derivative with antitumor activity and preparation method and application thereof | 天津匠新致成科技有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-118891261-A | Covalent EGFR inhibitors and methods of use thereof | 丹娜-法伯癌症研究院 | 2024-11-01 | — | — | CN | disclosed |
| US-20240352021-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-10-24 | — | — | US | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240293406-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | IMPACT BIOMEDICINES INC (US) | 2024-09-05 | — | — | US | disclosed |
| EP-4419529-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-1363904-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003033476-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0997460-B1 | Benzothiophene compounds as antithrombotic agents and intermediates | LILLY CO ELI (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002062787-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| US-6133262-A | 3-AMINOBENZO(B)THIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0997460-A1 | Benzothiophene compounds as antithrombotic agents and intermediates | ELI LILLY AND COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
| US-3957999-A | ADMINISTERING | THE BOOTS COMPANY (EN) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | LTA4H 4513/4885PTGS2 1351/4885PTGS1 1345/4885 |
| US-20240352021-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | LTA4H 3430/4885PTGS2 1771/4885PTGS1 1388/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | LTA4H 3846/4885PTGS2 2287/4885PTGS1 2858/4885 |
| US-12391676-B2 | BRD4-JAK2 inhibitors | BRD4, BICRA, JAK2 | LTA4H 2445/4885PTGS2 1493/4885PTGS1 1375/4885 |
| US-20240293406-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | JAK2, NPM1, MCL1 | LTA4H 3892/4885PTGS2 1515/4885PTGS1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.